BioNTech has announced the acquisition of fellow German biotech CureVac in an all-stock transaction valued at approximately $1.25 billion. Under the agreement, CureVac shareholders will receive about ...

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

GSK agrees €1.4bn deal to take full control of CureVac's mRNA vaccines for flu and COVID-19, as CureVac slashes staff and pivots to oncology.

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an all-stock deal valued at around $1.25 billion. Under the terms of the ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.

News on vaccines including HPV vaccine, shingles vaccine, bird flu vaccines and more. Read the latest research on vaccination risks and complications.